Flavopiridol (alvocidib) was identified as a potent CDK9 inhibitor and the first-in-class CDK inhibitor that has entered clinical trials in AML [175,176], followed by BAY-1143572 [177], and the pan-CDK inhibitors dinaciclib [178] or TG02 [179]. This evidence concerns the gene CDK9 and acute myeloid leukemia.